KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Non-Current Liabilities (2017 - 2025)

Historic Other Non-Current Liabilities for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $32.6 million.

  • Amneal Pharmaceuticals' Other Non-Current Liabilities rose 2459.33% to $32.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.6 million, marking a year-over-year increase of 2459.33%. This contributed to the annual value of $50.9 million for FY2024, which is 7150.17% up from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Other Non-Current Liabilities is $32.6 million, which was up 2459.33% from $25.8 million recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Other Non-Current Liabilities peaked at $87.5 million during Q4 2022, and registered a low of $23.2 million during Q1 2025.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $41.5 million (2023), whereas its average is $49.0 million.
  • In the last 5 years, Amneal Pharmaceuticals' Other Non-Current Liabilities surged by 12483.61% in 2022 and then tumbled by 6606.87% in 2023.
  • Amneal Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $38.9 million in 2021, then soared by 124.84% to $87.5 million in 2022, then tumbled by 66.07% to $29.7 million in 2023, then skyrocketed by 71.5% to $50.9 million in 2024, then crashed by 35.9% to $32.6 million in 2025.
  • Its last three reported values are $32.6 million in Q3 2025, $25.8 million for Q2 2025, and $23.2 million during Q1 2025.